Source and scope
This summary is bounded to the recommendations, population and decisions covered by 2021 guidelines for the management of dyslipidemia for cardiovascular disease prevention. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CCS lipids
Source-attributed clinical priorities
- Suspect familial hypercholesterolemia from markedly elevated LDL cholesterol, premature atherosclerotic disease and family history.
- Exclude important secondary causes while beginning guideline-directed lipid lowering when the phenotype is convincing.
- Arrange family cascade assessment and specialist input according to provincial genetic and lipid-clinic pathways.
- Use a validated clinical diagnostic approach and document the pedigree across multiple generations.
sources for this section:CCS lipids
Practical assessment and management workflow
1
Repeat a fasting or nonfasting lipid profile and exclude hypothyroidism, nephrotic, hepatic and medication causes.
2
Assess premature coronary disease, tendon xanthomas and first-degree family lipid and event history.
3
Begin intensive LDL-lowering and refer for lipid-specialist or genetic assessment where available.
4
Arrange cascade screening and follow response and adherence longitudinally.
sources for this section:CCS lipids
Safety, red flags and urgent escalation
- Do not delay treatment solely because genetic testing is unavailable or negative.
- Address pregnancy planning because lipid-lowering medicines have different reproductive safety.
- Escalate children and severe phenotypes through a specialist family-lipid pathway.
sources for this section:CCS lipids
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CCS lipids
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CCS lipids
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Cardiovascular Society2021 guidelines for the management of dyslipidemia for cardiovascular disease preventionaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.